Clinical Trials Logo

Filter by:
NCT ID: NCT05293821 Not yet recruiting - Clinical trials for To Demonstrate Clinical Performance of the TriQuik Invitro Diagnostic Device

Multicenter Performance Study of TriQuik Invitro Diagnostic Device

Start date: April 2023
Phase:
Study type: Observational

This prospective and historical clinical study is designed to test the performance of the Genlantis TriQuik test kit (Cassette). The primary goal is to establish the sensitivity and specificity (i.e. how accurate the test is) when compared to the same patient's medical history. Previous tests were performed on serum and whole blood specimens. A total of 607 serum specimens1 were collected for evaluation and comparison of the performance of the TriQuik Hepatitis B Surface Antigen (HBsAg) Test with a licensed commercial HBsAg EIA. 84 of 85 positive serum samples testing by the licensed commercial HBsAg EIA were reactive with TriQuik HBsAg Test and 520 of 522 negative samples testing by the licensed commercial HBsAg EIA were tested negative with TriQuik HBsAg Test.

NCT ID: NCT05312216 Not yet recruiting - Clinical trials for Hepatocellular Carcinoma

Durvalumab Plus Lenvatinib as First-line Treatment for Unresectable Hepatocellular Carcinoma

Start date: April 2023
Phase: Phase 2
Study type: Interventional

This is a phase II, open-label study to evaluate the efficacy and safety of Durvalumab plus Lenvatinib as first-line treatment in patients with unresectable hepatocellular carcinoma.

NCT ID: NCT05320939 Not yet recruiting - COPD Clinical Trials

Immunological Basis for Mepolizumab Activity in COPD

Start date: April 2023
Phase: Phase 2
Study type: Interventional

The current literature suggests that the mode of action of mepolizumab is to bind with Interleukin (IL)-5 and block the interaction of IL-5 with the IL-5Ra receptor on eosinophils. This removal of IL-5 may not explain all of the effects of mepolizumab. The investigators propose a set of studies to systematically examine the spectrum of effects of this drug on the immune system.

NCT ID: NCT05398016 Not yet recruiting - Anxiety Clinical Trials

Task Sharing for Anxiety

Start date: April 2023
Phase: N/A
Study type: Interventional

This single-arm pilot clinical trial will evaluate the feasibility, acceptability, and engagement of target mechanism, and preliminary impact of a low-intensity behavioral intervention for mild-to-moderate anxiety disorders. Treatment will delivered by trained lay counselors (n = 5) to patient participants (n = 15).

NCT ID: NCT05406323 Not yet recruiting - Fall Clinical Trials

Web-Based Fall Prevention Program for Elderly

Start date: April 2023
Phase: N/A
Study type: Interventional

Fall is one of the most common problems experienced by the elderly, is an important public health problem in many societies. Falls are one of the leading causes of fatal and non-fatal injuries in the elderly. An average of one-third of individuals aged 65 and over have a fall at least once each year. The research will be carried out on the web page that on fall prevention prepared within the scope of this project. The aim of this project is to assess the effect of Web-Based Fall Prevention Program on falling, fall risk and fear of fall.

NCT ID: NCT05407545 Not yet recruiting - Clinical trials for Lower Limb Amputation Above Knee (Injury)

Evaluation of a Motorised Prosthetic Knee

MOKI-B
Start date: April 2023
Phase: N/A
Study type: Interventional

The study will investigate the effect over time of the Power Knee (Össur) on performance during daily activities in people with a unilateral transfemoral amputation, will determine subjective feelings and gait kinematics over time during daily activities and will investigate the association between subjective feelings and objective outcomes of performing daily activities.

NCT ID: NCT05428592 Not yet recruiting - SARS-CoV-2 Clinical Trials

Clinical Trial of SARS-CoV-2 mRNA Vaccine(LVRNA009) as Heterologous Booster in Islamabad

Start date: April 2023
Phase: Phase 3
Study type: Interventional

This study is a randomized, blinded, parallel-controlled phase 3 clinical trial. The study intent to evaluate the immunogenicity and safety of SARS-CoV-2 mRNA Vaccine (LVRNA009) as heterologous booster in participants aged 18 years and older vaccinated 2 doses Inactivated SARS-CoV-2 Vaccine.

NCT ID: NCT05433805 Not yet recruiting - Clinical trials for Myelodysplastic Syndromes

Lifestyle-modifying Interventions in Low-risk MDS Patients

MDS-LIME
Start date: April 2023
Phase: N/A
Study type: Interventional

Myelodysplastic syndromes (MDS) are acquired clonal stem cell diseases characterized by hematopoietic cell dysplasia, cytopenia, and the risk of progression to acute myeloid leukemia. In addition to clonal changes in the hematopoietic stem and progenitor cells itself, growing evidence suggests that inflammatory and metabolic changes in the bone marrow microenvironment play an important role in disease development and maintenance of the malignant clone. The positive impact of dietary interventions (e.g. fasting) and physical activity on inflammation and metabolic parameters could be shown in various benign inflammatory disease entities (e.g. atherosclerosis, chronic renal insufficiency, cystic fibrosis etc.). The aim of this study is to describe the hematological, metabolic, inflammatory, and microbiological changes after combined lifestyle-modifying interventions (outpatient physiotherapy and fasting mimicking diet (FMD) in patients with low-risk MDS.

NCT ID: NCT05440773 Not yet recruiting - Clinical trials for Asymptomatic Malaria

Emptying Malaria Reservoirs to Accelerate Malaria Elimination in High Transmission Settings

Start date: April 2023
Phase: N/A
Study type: Interventional

The study is a Phase 2 randomized controlled, partial-blind, parallel group study in plasmodium infected asymptomatic adults 18 years and older, with 8 study arms. It will use the adapted Zelen design, which has two steps in the consent process. In the first step, there is an informed consent from all participants for a cohort lifestyle study. According to this consent, participants are randomized without knowledge about the detailed protocol. In the second step, only participants from the intervention group will receive the information about the intervention and the second consent will be obtained from them. The participants who will decline to participate to an intervention will continue in the cohort study, as the control group.

NCT ID: NCT05450302 Not yet recruiting - Cardiac Arrhythmias Clinical Trials

Assessing the Predictive Value of High Frequency Algorithm of PURE EP for Low Amplitude Signal Detection

Start date: April 2023
Phase:
Study type: Observational

Prior multicenter study demonstrated superiority of PURE EP to conventional mapping. This superiority was seen when comparing small, fractionated signals of interest, near-field vs far-field distinction, and general signal quality (2). Hence, investigators propose a retrospective study to assess the predictive value of high frequency algorithm (HFA) for identifying local physiologic signal under 0.3 mV distinctive of noise.